Found (460) clinical trials

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.

This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

The duration of the study for the patients will include a period for screening of up to 21 days (or up to 28 days for women who can become pregnant). Patients will continue study treatment until disease progression, unacceptable adverse reaction, patients' wish or other reason of discontinuation. During follow-up, ...

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil ...

Detailed description The purpose of this research study is to investigate the safety of an active implantable (radiological) medical device OncoSil, when implanted into patients with pancreatic cancer, in conjunction with Standard of Care (SOC) chemotherapy. OncoSil, is an experimental treatment and carries the active treatment "radioactive Phosphorous (32P)" inside ...

Patients will be randomized in a 1:1 ratio to 2 treatment arms (durvalumab or SOC therapy). The Co-primary objectives of this study are to assess the efficacy of durvalumab compared to SoC in terms of PFS (Progression Free Survival) and OS (Overall Survival) in patients with NSCLC

This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.